The Canadian Association of Pathologists and its National Standards Committee for High Complexity Testing (CAP-ACP NSCHCT) identified the need to generate and publish Canadian guidelines to assist clinical laboratories in setting up predictive PD-L1 IHC testing. These guidelines do not pertain to the professional practice of oncologists; they pertain solely to the development and validation of PD-L1 testing by clinical laboratories.
Prior to submission for peer-reviewed publication, we invite CAP-ACP members to review and provide comments on the draft recommendations during this open review period of April 15-30, 2019.
Comments should be emailed directly to our supporting agency for this review period, to the attention of Sonia Hoole at email@example.com. We ask that reviewer’s contact details are included with their comments so that we may ask for further clarification directly as necessary.
I thank you for your time and consideration.
Dr Emina Torlakovic
Chair, CAP-ACP NSCHCLT / IHC